下载App
扫码立即下载
  • 下载App

    扫码立即下载

  • 在线客服

    登录后咨询在线客服
+
恭喜您!
成功领取价值超 5000港元/年的高级行情
前往体验 >>
多维分析
公司估值 资金追踪 卖空分析
09939 开拓药业-B
12.520
-0.440-3.40%
显示同比
不显示
隐藏空行
(FY)2021/12/31(Q6)2021/06/30(FY)2020/12/31(Q6)2020/06/30
Per Share IndicaTor
Operating Cash Flow Per Share
-170.81% -3.3177 -178.46% -1.3388 86.67% -1.2251 -- -0.4808
Cash Flow Per Share
-110.42% -0.3217 -89.09% 0.5167 26% 3.0869 -- 4.7347
Operating Income Per Share
-- 0.108 -- -- -- -- -- --
Net Asset Per Share
7.68% 5.2231 25.5% 6.6977 -67.44% 4.8503 -- 5.337
Basic Earning Per Share
-48.13% -2.8865 -41.8% -1.1177 82.04% -1.9486 83.76% -0.7882
Diluted  Earning Per Share
-48.13% -2.8865 -41.8% -1.1177 82.04% -1.9486 83.76% -0.7882
Profitability
Gross Profit Ratio
-- 100.000% -- -- -- -- -- --
Operating Profit Ratio
-- -2452.750% -- -- -- -- -- --
Net Profit Ratio
-- -2460.036% -- -- -- -- -- --
Earning Before Tax Ratio
-- -2460.036% -- -- -- -- -- --
ROE
1.49% -53.980% 0.56% -17.849% 26.07% -54.796% 59.27% -17.949%
ROA
-1.61% -43.558% -8% -15.400% 8.99% -42.869% 42.49% -14.259%
Yield Quality
Operating Cash To Total Revenue
-- -3071.374% -- -- -- -- -- --
Capital Structure
Debt Assets Ratio
7.59% 19.963% -41.96% 10.032% -44.11% 18.555% -63.52% 17.286%
Equity Multipler
1.76% 1.2494 -8.06% 1.1115 -17.98% 1.2278 -36.39% 1.209
Debt Equity Ratio
9.48% 24.942% -46.64% 11.151% -54.16% 22.782% -76.8% 20.898%
Current Assets To tatal Assets
-3.83% 73.786% -3.53% 80.079% 92.46% 76.729% 164.38% 83.009%
Non Current Assets To Total Assets
12.64% 26.214% 17.24% 19.921% -61.3% 23.271% -75.23% 16.991%
Current Liabilities To tatal Liabilities
7.99% 53.228% -54.09% 29.041% -36.49% 49.290% -16.37% 63.262%
Non Current Liabilities To Total Liabilities
-7.76% 46.772% 93.15% 70.959% 126.51% 50.710% 50.86% 36.738%
Solvency
Current Ratio
-17.23% 6.9441 262.08% 27.4853 442.22% 8.3895 766.68% 7.5909
Quick Ratio
-- 5.3451 -- 27.1124 -- -- -- --
Operating Profit To Current Liabilities
-28.16% -3.8209 -470.7% -4.6375 -85.89% -2.9814 -10.22% -0.8126
Operrating Cash Flow To Current Liabilities
-112.71% -4.7846 -805.86% -6.1725 -40.64% -2.2493 -0.42% -0.6814
Share Equity Without Minority Interest To Total Liabilities
-8.66% 4.0093 87.41% 8.9677 118.14% 4.3894 331.01% 4.7852
Operating Cash Flow To Total Liabilities
-129.7% -2.5467 -315.84% -1.7926 10.68% -1.1087 16.02% -0.4311
Operating Profit To Total Liabilities
-38.39% -2.0338 -161.98% -1.3468 -18.05% -1.4696 7.82% -0.5141
Operating Capacity
Current Assets Turnover(T)
-- 0.0236 -- -- -- -- -- --
Fixed Assets Turnover(T)
-- 0.1741 -- -- -- -- -- --
Total Assets Turnover(T)
-- 0.0177 -- -- -- -- -- --
Growth Ability
Operating Revenue GR 3Y
-- 5155.651% -- -- -- -- -- --
Operating Profit GR 3Y
28.15% -761.221% -- -820.489% -- -1059.499% -- --
EBT GR 3Y
28.77% -731.874% -- -774.811% -- -1027.444% -- --
Net Profit GR 3Y
28.78% -731.874% -- -774.811% -- -1027.606% -- --
Net Profit Attributable To The Parent Company GR 3Y
28.78% -731.874% -- -774.811% -- -1027.606% -- --
Total Assets GR 3Y
-87.05% 421.964% -- -- -- 3259.604% -- --
Share Equity Without Minority Interest GR 3Y
-99.77% 603.138% -- -- -- 261258.973% -- --
Equity GR 3Y
-99.77% 603.138% -- -- -- 261258.973% -- --
Total Liabilities GR 3Y
-69.68% 156.738% -- -- -- 516.911% -- --
Basic Earning Per Share GR 3Y
48.96% 49.112% -- 46.762% -- 32.970% -- --
Other Indicators
Currency Unit
港元港元港元港元

Q6、Q9、FY为累计季报:Q6 为中期报告;Q9 为第三季报;FY为年报。

环比数据来源于季报,环比 = (本期 - 上期)/上期 * 100%

公司概况 更多
开拓药业有限公司是一家临床阶段新药开发商,专注于研究癌症药物及其他雄激素受体(AR)相关疾病药物。该公司的主要在研药物是普克鲁胺。该药物正在中国进行转移性去势抵抗性前列腺癌(mCRPC)的III期临床试验。该公司处于临床阶段在研药物还包括一种II期小分子在研药物Pyrilutamide、一种II期单克隆抗体在研药物ALK-1、一种I期mTOR抑制剂Detorsertib、以及一种hedgehog信号转导途径抑制剂GT1708F。
董事长: 童友之
所属市场: 香港主板
上市日期: 2020/05/22
富途热股榜
港股美股沪深
交易热度搜索热度资讯热度
名称代码最新价涨跌幅

加载中...

自选
回到顶部